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Strengths and limitations of this study
 ► Novel and comprehensive approaches for the as-
sessment of the presence of central sensitisation 
(CS).
 ► Extensive amount of measurements from multiple 
domains for the determination of functioning status.
 ► Longitudinal study with measurements at baseline 
and discharge of an interdisciplinary rehabilitation 
programme implemented as ‘Care As Usual’.
 ► Strategies allocated to promote participation and 
adherence, and to mitigate selection bias to the 
largest extent possible.
 ► Statistical analyses are performed with selections of 
CS and functioning measurements, and these selec-
tions may influence study results.
ABSTRACT
Introduction A relevant subsample of patients with 
chronic low back pain (CLBP) have manifested augmented 
central pain processing, central sensitisation (CS). Patients 
with CLBP have limited functioning and participation. 
Theoretically, physical functioning in patients with CLBP 
can plausibly be linked to CS; however, evidence to explain 
such association is scarce. Moreover, there is no gold 
standard for CS diagnosis. The objectives of the study 
are: (1) to analyse the association between instruments 
assessing reference symptoms and signs attributed to 
CS; (2) to analyse whether reference symptoms and 
signs attributed to CS are associated with functioning 
measurement outcomes; and (3) to analyse whether 
changes (between baseline and discharge) in reference 
symptoms and signs attributed to CS are related to changes 
in each of the functioning measurement outcomes.
Methods and analysis A cross- sectional and longitudinal 
observational study is performed with measurements taken 
at baseline and discharge of an interdisciplinary rehabilitation 
programme. A sample size of 110 adult patients with CLBP 
has been calculated for the study. CS measurements are: 
Central Sensitisation Inventory, quantitative sensory testing 
and heart rate variability. Functioning measurements are: 
lifting capacity, maximal aerobic capacity, accelerometry and 
reported functioning. Statistical analyses to be performed 
are: (1) correlation between CS measurements, (2) multiple 
regression between functioning (dependent variable) and 
CS measurements (independent variable), and (3) multiple 
regression between changes in scores of functioning 
(dependent variable) and CS measurements (independent 
variable), and corrected for sex and age.
Ethics and dissemination The study obtained the 
clearance to its implementation from the Medical Research 
Ethics Committee of the University Medical Center 
Groningen in July 2017. The results will be disseminated 
through scientific publications in peer- reviewed journals, 
presentations at relevant conferences, and reports to 
stakeholders.
Trial registration number NTR7167/NL6980.
InTRoduCTIon
Background
Twenty per cent of the general population 
experiences prolonged or recurrent pain for 
at least 3 months, such pain is then consid-
ered to be chronic.1 2 Low back pain is the 
principal cause of years lived with disability 
and workdays lost in Europe and worldwide,3 
and its sequelae affect 9% of the global 
population.4 Moreover, although there are 
several treatment intervention strategies 
available for patients with chronic low back 
pain (CLBP), treatment effect sizes have 
only been moderate.5 Such evidence may 
explain why 40% of the patients are not 
satisfied with the treatment received.2 The 
economic consequences of chronic pain 
include direct costs of medical care and 
pain management treatments, as well as indi-
rect costs of decreased work productivity 
and sick leave, and of disability and sickness 
retirement.2 6 The indirect costs determine 
86%–88% of the total costs produced by 
patients with CLBP.7 8 In particular, in the 
Netherlands, the costs derived from back 
pain to Dutch society were 3.5 billion in 2007, 















pen: first published as 10.1136/bm





2 Ansuategui Echeita J, et al. BMJ Open 2020;10:e031592. doi:10.1136/bmjopen-2019-031592
Open access 
In the past decennia, a relevant subsample of patients 
with chronic pain, including individuals with CLBP, have 
shown an increased responsiveness to noxious and non- 
noxious stimuli, described as central sensitisation (CS).9 
CS is a result of an imbalance in the nociceptive path-
ways (‘pain pathways’) and supraspinal structures due to 
an amplified facilitation and/or reduced inhibition.10–12 
The phenomenon, CS, is manifested by an amplified 
pain perception regarding its intensity (hyperalgesia 
and allodynia), duration (aftersensations and temporal 
summation) and distribution (expansion of the receptive 
field), as well as a reduced conditioned pain modulation 
(CPM).12 There is currently no gold standard for CS diag-
nosis. Identifying reference clinical symptoms and signs, 
however, may indicate the presence of CS: dispropor-
tionate pain, diffuse distribution, allodynia and hyperal-
gesia, hypersensitivity unrelated to mechanical stimulus 
but rather to environmental sensations (light, tempera-
ture, noise or other stressors), maladaptive psychosocial 
factors and low vagal nerve activity.13–16
Chronic pain is a multifactorial condition which has 
an impact on physical or body structures and functions, 
on psychological processes and on daily activities and 
quality of life of individuals.2 17 18 Limited functioning or 
capacity to perform everyday tasks (essential for an inde-
pendent living) affects individuals with chronic pain in 
their mobility and self- care, social relationships, work and 
leisure.19 Individuals’ functioning is composed of body 
functions (body level)—described by impairments they 
experience—and of activities and participation (personal 
and social levels, respectively)—described by capacity 
and performance tests.18 20 An extensive overview of the 
functioning status is best obtained when the assessment 
includes suitable and relevant measures from multiple 
domains of daily living. In particular, lifting capacity, 
physical activity (PA), aerobic capacity or daily activities 
participation are measures that account for the multiple 
operationalisations of functioning in the daily living.
Patients with CLBP are likely to be less physically active, 
and be more deconditioned and disabled.3 21–23 A subsa-
mple of patients with CLBP can manifest symptoms and 
signs of CS being present.9 Because patients with CS 
are more reactive to stimuli and their pain experience 
is enhanced, the presence of CS and/or higher levels 
of CS could plausibly be associated with lower physical 
functioning and participation in patients with CLBP, and 
vice versa. More severe symptomatology of CS, decreased 
parasympathetic/vagal activity or altered somatosensory 
responses have been associated with greater self- reported 
pain- related disability.24–30 However, the associations 
between altered somatosensory responses and self- 
reported disability were dependent on the site of testing, 
the stimuli and the type of tests performed. Also, CS has 
been assessed with different instruments that measure 
specific CS clinical symptoms,12 lacking a comprehensive 
assessment of CS in which various reference clinical symp-
toms are measured together. Moreover, functioning has 
most frequently been assessed with self- reported disability 
which is not exclusively representative of the functioning 
status of the patient.
The study described in this research protocol has been 
created to improve the assessment and management of 
pain and disability of centrally sensitised patients with 
CLBP and fill the existing gaps in knowledge. On the one 
hand, it intends to assist on the phenotyping of centrally 
sensitised patients with CLBP. To this purpose, an inte-
grated assessment of CS combining the use of various 
instruments which measure different reference clinical 
symptoms of CS is aimed. Instruments like Central Sensi-
tisation Inventory (CSI),31 quantitative sensory testing 
(QST)32 33 and heart rate variability (HRV)34 are non- 
invasive, feasible and assess different reference clinical 
symptoms and signs indicative of CS.12 In the absence of a 
gold standard, these instruments measure different refer-
ence indicators of CS and can also be complementary to 
describe CS. On the other hand, it intends to improve 
the understanding of CS phenomenon and its contribu-
tion to functioning status. Lifting capacity, PA levels and/
or PA distribution or patterns, aerobic capacity and daily 
activities participation are representative of several tasks 
of the daily living usually limited in patients with CLBP. 
These capacity and performance tests and self- reported 
functioning measures can give an extensive overview of 
the functioning status.
objective(s)
The objectives of the studies covered by this research 
protocol are:
1. To analyse the association between three instruments 
assessing reference symptoms and signs attributed to 
CS in patients with CLBP: CSI, QST and HRV.
2. To analyse whether reference symptoms and signs at-
tributed to CS are associated with functioning measure-
ment outcomes in patients with CLBP. Specifically, to 
analyse the association between the three instruments 
assessing CS (CSI, QST and HRV) and: lifting capacity, 
aerobic capacity, PA levels and/or PA distribution or 
patterns, and patient- reported measurements.
3. To analyse whether changes (between baseline and 
discharge) in reference symptoms and signs attribut-
ed to CS are related to changes in each of the func-
tioning measurement outcomes in patients with CLBP. 
Specifically, to analyse whether decreases in CS de-
scribed as: a lower CSI score, an increase in the pain 
thresholds (QST) and an increase in parasympathetic/
vagal tone (HRV) are related to a better functioning 
described as: an increase in lifting capacity, an increase 
in aerobic capacity, an increase in PA levels and/or a 
change in PA distribution or patterns, and better out-
come scores in patient- reported measurements.
METhodS And AnAlySES
Study design
An observational study project with both cross- sectional 
and longitudinal designs is being conducted from 
copyright.
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September 2017 to September 2019 in the Center for 
Rehabilitation of the University Medical Center Gron-
ingen (CvR- UMCG) in the Netherlands.
Patient and public involvement
The personnel of the CvR- UMCG collaborate in the study, 
in particular, the Pain Rehabilitation team during patient 
management and data collection process and the central 
exercise lab team on data collection process. The authors 
wish to express their gratitude to the collaborators and to 
the patients who participate.
Participants
Consecutive patients between 18 and 65 years of age at 
the time of recruitment who are primarily referred to 
the outpatient Pain Rehabilitation Department of the 
CvR- UMCG due to a chronic primary low back pain and 
who are assessed for the interdisciplinary pain rehabilita-
tion programme are eligible to participate in the study. 
Chronic primary low back pain is defined as a low back pain 
recurrent for more than 3 months, related to emotional 
distress and/or functional disability and whose pain is 
not a result of any other diagnosis35 even if patients may 
have undergone surgery in the past. Additionally, patients 
are invited to the study if they are mentally competent 
and can follow instructions. Furthermore, patients are 
excluded from the study if, based on their file, they: have 
a specific diagnosis that would better account for the 
symptoms (cancer, osteoporosis, rheumatological inflam-
matory diseases and/or spinal fractures), have neuralgia 
and/or radicular pain in the legs, have severe psychiatric 
disorders, show sensitivity alterations in measurement 
location(s), are pregnant (or planning to be), have any 
specific contraindication according to the standards of 
practice guidelines of the assessments that they are going 
to be subjected to,36 37 or take any medication that may 
interfere with the assessment outcomes such as calcium 
channel blockers on HRV. CS- related comorbidities (ie, 
fibromyalgia, osteoarthritis or chronic fatigue syndrome) 
are no reason for exclusion from the study. The use of 
opioid or pain- related medication is neither a criterion 
for exclusion and such information is recorded.
Procedures
Measurements are performed as part of ‘Care As Usual’ 
(CAU) for outpatients following the pain rehabilitation 
guidelines of the CvR- UMCG. However, not all measure-
ments of the research protocol belong to the battery of 
assessments of the CvR- UMCG, as pointed out in the 
legend of figure 1.
During the first appointment of the patients with the 
rehabilitation physician, patients are invited to partici-
pate in the studies if based on their file they are eligible 
according to the criteria defined for the studies. Eligible 
patients who are invited to participate and receive 
information about the study, but have not reacted, are 
contacted in a week’s time to remind them about the study 
participation. Those who sign the informed consent, fill 
in forms with their relevant personal information during 
the baseline assessment and are given vouchers for the 
travel expenses during the discharge assessment. Partici-
pating patients follow CAU trajectory with the Pain Reha-
bilitation team in terms of assessments, screening and 
implementation of the interdisciplinary rehabilitation 
programme. As part of the research protocol, the perfor-
mance of additional assessments and filling up of ques-
tionnaires on CS and functioning are required. CSI, lifting 
capacity and HRV results are collected as CAU. Aerobic 
capacity, QST, objective PA monitoring, and pain inten-
sity and functioning questionnaires’ results are collected 
as additional to CAU. All CS measurements, objective PA 
monitoring and capacity tests are measured at two time 
points, baseline and discharge. Pain intensity and func-
tioning questionnaires, on the other hand, are measured 
at 13 time points, baseline and once a week during the 
12- week rehabilitation programme. Pain Disability Index 
(PDI) is the only functioning questionnaire collected as 
CAU at baseline but as additional during the rehabilita-
tion programme. A diagram of the project procedure is 
presented in figure 1.
Measurements
CS measurements
In order to comprehensively assess the symptoms and 
signs attributed to CS, data are obtained from a ques-
tionnaire (CSI) and two physical assessments (QST and 
HRV).
Central Sensitisation Inventory
The inventory is a self- reported questionnaire with two 
sections to estimate the severity of CS- related symptoms. 
Section A is a 25- item questionnaire to assess the pres-
ence of the most common CS- related symptoms. Each of 
the questions is measured on a 5- point Likert scale from 
0 (never) to 4 (always), and the total score ranges from 
0 to 100, where higher scoring is associated with more 
severe symptomatology. Section B is a 10- item question-
naire to assess the previously diagnosed CS syndromes 
(CSS) and/or conditions related to CS. Higher amount 
of CSS is associated with higher chances of CS being 
present. This instrument has shown excellent test–retest 
reliability (intraclass correlation coefficient (ICC)=0.82–
0.97) and internal consistency (Cronbach’s α=0.87–0.91) 
in the general population and in patients with chronic 
pain,31 38–40 as well as good concurrent validity (sensi-
tivity=81%, specificity=75%) for CSS diagnosis within 
patients with chronic pain.38 For the purposes of the 
study the Dutch translation of the CSI is used,41 which has 
also shown excellent internal consistency (Cronbach’s 
α=0.91) and test–retest reliability (ICC=0.91 and 0.88) 
in controls and in patients with chronic musculoskeletal 
pain, respectively.42 The psychometric information of CSI 
in patients with CLBP is not known.
Quantitative sensory testing
A battery of standardised sensory tests quantifies the 
function of the somatosensory system. QST tests the 
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Figure 1 Flow chart of the project procedure. *Measurements obtained which do not belong to Care As Usual (CAU) of the 
Pain Rehabilitation Department of the Center for Rehabilitation of the University Medical Center Groningen (CvR–UMCG). 
CLBP, chronic low back pain; CSI, Central Sensitisation Inventory; HRV, heart rate variability; PDI, Pain Disability Index; QST, 
quantitative sensory testing; Rand36- PF, Rand36 Physical Functioning subscale; VAS, Visual Analogue Scale; WAS, Work Ability 
Score.
characteristics of various sensation and nociceptive 
processes as representative of afferent nerve fibres and 
central pathways performance. The whole assessment 
lasts for 1 hour, and it consists of six sensory tests, which 
are measured in seven different predefined body loca-
tions: one training location to familiarise the patient with 
the tests, the most painful location (as pointed out by the 
patient), and five control locations. See online supple-
mentary material 1 for full description of body locations. 
The standardised instructions of the sensory tests are read 
to the patient at each test performance. Of the tests, five 
consist of mechanical stimuli based on and performed 
following the QST examination of the German Research 
Network on Neuropathic Pain (DFNS) protocol,32 and 
one for CPM following the Nijmegen- Aalborg Screening 
QST protocol.33 43 Overall, the DFNS protocol has shown 
good test–retest (mean r=0.86) and interobserver reli-
ability (mean r=0.83) in patients with affections in the 
somatosensory system either with or without pain.44 For 
the purpose of avoiding bias due to the order of the 
measurements and locations, a counterbalancing proce-
dure is established, which accounts for the locations and 
the measurements to be made. This procedure provides 
three different assessment order groups, all of which 
copyright.
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begin with the measurements at the training location 
and end with the CPM test. An additional counterbal-
ancing procedure has been made for allocating patients 
to these assessment order groups (either 1, 2, or 3). Every 
nine patients, a different allocation order is performed 
to ensure a similar amount of QST assessments per 
group. All assessors are trained in the QST protocol. The 
following sensory tests are performed:
 ► Dynamic mechanical allodynia (DMA)—to test the pres-
ence of abnormal stimuli- evoked pain—is assessed 
with a soft brush (SENSElab, Brush-05, Somedic, 
Hörby, Sweden) that is swiped 1–2 cm over the skin. 
This is performed on a single repetition and on a 
train of three repetitions (wind- up response). At each 
of the seven body locations (see online supplementary 
material 1) it is recorded whether the patients feel the 
sweeping and its pain intensity with a numeric rating 
scale (NRS) ranging from 0 (no pain) to 100 (most 
intense pain imaginable) for both the single swipe 
and the series.45 46 The DMA (ratio) is calculated as: 
DMA=(NRS-3/NRS-1). If NRS-1 is 0, the DMA for 
that location cannot be calculated and it will be regis-
tered as a missing value. The DMA test according to 
the DFNS protocol has shown to have good test–retest 
(r=0.87) and interobserver reliability (r=0.79).44
 ► Mechanical pain threshold (MPT)—to test the ability 
to perceive sharp, pricking or stinging stimuli—is 
assessed with a set of standardised weighted pinprick 
stimulators with seven different intensities (the 
PinPrick Stimulator Set, MRC Systems, Germany) 
and with a modified method of limits. Starting at the 
lowest intensity (8 mN), it progressively increases until 
patients report the stimulus to change from touch to 
painful (sharp, pricking or stinging). The intensity of 
the pinprick that produces the first painful stimulus 
in millinewtons is recorded in each of the seven loca-
tions (see online supplementary material 1).46–49 The 
MPT test according to the DFNS protocol has shown 
to have good test–retest (r=0.80) and interobserver 
reliability (r=0.80).44
 ► Wind- up ratio (WUR)—to test the nervous system’s 
painful stimuli temporal summation or responsive-
ness to repeated noxious stimuli. Such test is assessed 
with a suprathreshold pinprick stimulator of 256 
mN (the PinPrick Stimulator Set, MRC Systems, 
Germany), which is applied on a single repetition and 
on a train of 10 repetitions in an area of 1 cm2 with 
intervals of 1 s (wind- up response). The pain inten-
sity measured with an NRS ranging from 0 (no pain) 
to 100 (most intense pain imaginable) for both the 
single repetition and the series is recorded in each 
of the seven body locations (see online supplemen-
tary material 1).50 51 The WUR (ratio) is calculated as: 
WUR=(NRS-10/NRS-1). If NRS-1 is 0, the WUR for 
that location cannot be calculated and it will be regis-
tered as a missing value. The WUR test according to 
the DFNS protocol has shown to have poor test–retest 
(r=0.67) and interobserver reliability (r=0.56).44
 ► Mechanical detection threshold (MDT)—to test the ability 
to detect light touch—is assessed with a standardised 
set of von Frey filaments (OptiHair2- Set, Marstock 
Nervtest, Germany) with a modified method of 
limits.52 53 Starting at the intensity of 16 mN, the stim-
ulus application progressively decreases until patients 
do not report any sensation. The intensity of the fila-
ment that is not perceived in millinewtons is recorded 
in each of the seven body locations (see online supple-
mentary material 1).54 The MDT test, according to the 
DFNS protocol, has shown to have good test–retest 
(r=0.90) and interobserver reliability (r=0.89).44
 ► Pressure pain threshold (PPT)—to test the ability to 
perceive pressure pain stimuli on muscles—is assessed 
with an electronic pressure algometer (Force Ten 
FDX, Wagner Instruments, USA). With this tool, the 
pressure in the contact point (1 cm2 tip) is progres-
sively but steadily increased until patients report to feel 
pressure change towards painful (burning, drilling 
or aching). The intensity in newtons when pressure 
becomes painful and its pain intensity with an NRS 
ranging from 0 (no pain) to 100 (most intense pain 
imaginable) scale is recorded in each of the seven 
body locations (see online supplementary material 
1).32 The PPT test according to the DFNS protocol has 
shown to have good test–retest (r=0.88) and interob-
server reliability (r=0.84).44
 ► CPM—to test the nervous system’s descending pain 
processing. The CPM test methodology selected for 
this study follows the recommendations of the EFIC 
meeting (2013).55 The pain modulation is assessed by 
means of PPT tests (test stimuli) in a distant location 
from patients’ dominant hand (musculus deltoid and 
musculus quadriceps of the non- dominant side, see 
online supplementary material 1) before and after 
immersing the dominant hand in a bucket full with ice 
and cold water (cold conditioning stimuli). First, PPT 
measurements at distant locations are made; then, 
patients immerse the dominant hand in the bucket for 
as long as they possibly can with a maximal duration 
of 3 min; finally, PPT measurements are repeated. The 
PPT results, intensity in newtons and pain intensity 
with an NRS ranging from 0 (no pain) to 100 (most 
intense pain imaginable) scale, in both locations and 
the time the hand is immersed are recorded. The 
CPM (%) is calculated as: CPM=[(PPTpost–PPTpre)/
PPTpre]∗100, where lower values indicate lower alter-
ation on the nociceptive pathways.33 43 The CPM test, 
as the combination of the PPT handheld algometer 
and cold stimuli, has shown to be one of the most 
reliable methods with a modest test–retest reliability 
(ICC=0.49 and coefficient of variation=63.6%).56
Heart rate variability
The test provides an indication of the function and 
balance of the autonomic nervous system (ANS), which 
is responsible for the control of internal functions 
including self- regulation, adaptability and resilience 
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capacities.57 The ANS is susceptible to mental and 
emotional processes, which in turn can produce an 
imbalance in self- regulation (affecting, among others, 
heart rate (HR)) by a hyperactivation of the sympathetic 
tone and reduced parasympathetic/vagal tone.15 34 HRV 
testing can monitor heart rhythms, or time and pattern 
variation on HR and interbeat (RR) intervals, and can be 
used to assess the function of the ANS.58 59 The HRV test 
is performed by assessors trained by the HeartMath Insti-
tute, and the 5 minute protocol is executed to guarantee 
the comparison of the results as recommended by the task 
force for short- term recordings.58 Patients are instructed 
to sit calmly and breathe normally, while they have an ear 
pulse sensor placed which is connected to a computer.60 
The following measures are collected and recorded with 
the emWave PC software (emWave, HeartMath, Boulder 
Creek, California, USA): mean HR in beats per minute, 
mean RR interval in milliseconds; time domain measures 
in milliseconds as SD of normal- to- normal interval indi-
cator for cyclic components responsible of RR interval 
variability, root mean square of successive differences 
(RMSSD) for beat- to- beat variance in HR and parasym-
pathetic/vagal tone; frequency domain measures in 
ms2/Hz as very- low- frequency (0.0033–0.04 Hz) indi-
cator for long- term regulation and sympathetic tone, low 
frequency (0.04–0.15 Hz) for sympathetic and parasym-
pathetic/vagal tones and high frequency (0.15–0.40 Hz) 
for parasympathetic/vagal tone related to breathing rate; 
and normalised coherence indicator for HRV stable or 
regular pattern over time in percent, where higher scores 
mean more harmonic signal.
Physical functioning measurements
In order to determine the functioning status of indi-
viduals with chronic pain in multiple domains, data 
are obtained from two physical assessments (lifting and 
aerobic capacity tests), an accelerometer (PA level) and a 
battery of reported functioning questionnaires.
Lifting capacity test
The floor- to- waist lift capacity test is based on the Work-
Well Functional Capacity Evaluation (FCE) protocol61 
and is performed to measure patients’ work functioning 
or capacity. Such FCE lift test has been shown to have 
high test–retest (ICC=0.81) and inter- rater reliability 
(ICC=0.76) in patients with CLBP.62 63 Assessors are 
trained in the floor- to- waist lift capacity test procedure. 
Patients are given standardised instructions to repeti-
tively lift a crate with weights from a shelf at waist height 
to the floor and back. The test begins with a weight that 
can easily be lifted, progressively the load is increased and 
the test ends when the maximum capacity is reached. The 
final endpoint can be reached due to: cardiac endpoint 
(85% of maximum HR), biomechanical endpoint (unsafe 
increasing weight because of lack of load handling 
control), patient endpoint (patient decided to stop) 
and criterion endpoint (normal end of the test).64 The 
maximal load lifted in kilograms is recorded along with 
the endpoint reason, and the patient- reported and the 
assessor- observed mechanical effort as measured with 
Borg’s category ratio (CR-10) scale.65 Borg’s CR-10 scale 
ranges from 0 (at rest) to 10 (very, very hard), and has 
demonstrated to be a valid visual observation of the effort 
level of patients during their performance of a lifting 
capacity test.66
Aerobic capacity test
The maximal aerobic capacity is assessed with a cardiopul-
monary exercise test (CPET). The test is performed with 
a cycle ergometer (Ergoselect 200p or Ergoselect 200k, 
Ergoline, Bitz, Germany) following a defined continuous 
ramp protocol. Before any cycling begins, patients are 
interviewed about their daily activities, and their resting 
heart rhythm and function are recorded with an ECG 
(Assy Cam-14, GE Medical Systems, USA). Patients then 
have an unloaded warm- up of 3 minutes at 60–70 rotations 
per minute before the test begins. At the start of the test, 
an experienced exercise physiologist in discussion with 
a specialised physician or nurse determines the starting 
workload (25–100 W) and ramp (5–25 W increase per 
minute) depending on patients’ estimated fitness level. 
During the test, patients are asked to maintain a constant 
cadence while the working load is progressively being 
increased. Also, they are continuously being verbally 
encouraged to obtain their maximum performance. The 
maximal performance is determined by various parame-
ters: a temporary loss of strength and energy (=exhaus-
tion), a plateau in the peak oxygen uptake (VO2max), a 
respiratory exchange ratio higher than 1.15 and/or an 
HR higher than 85% of the predicted maximal HR.37 
Overall, the test lasts for 8–12 minutes and throughout the 
whole assessment patients are monitored on their cardiac 
activity with an ECG, on their blood pressure with a cuff 
algometer and on their ventilatory gases on a breath- by- 
breath basis with a metabolic cart (JAEGER Vyntus CPX, 
Jaeger, Germany, Hoechberg). The VO2max in mL/
min and per kilogram in mL/min/kg is collected as the 
mean of VO2 over the last 30 seconds of exercise. Along 
with VO2max, the following measures are collected: peak 
workload in watts, HR at end of test in beats per minute, 
breathing frequency at end of test in breaths per minute, 
expiratory tidal volume in litres, peak energy expendi-
ture in metabolic equivalent of task (MET), test duration 
in minutes, and the patient- reported and the assessor- 
observed mechanical effort as measured with Borg’s 
rating of perceived exertion (RPE) scale. Borg’s RPE 
scale ranges from 6 (no exertion at all) to 20 (maximal 
exertion)65 and has shown to be highly correlated with 
HR (r=0.74) and blood lactate (r=0.83),67 demonstrating 
to be a reliable instrument to measure work intensity.
PA levels
The objective measurements of PA levels are obtained 
by means of an accelerometer (ActiGraph GT9X Link, 
ActiGraph, Pensacola, FL, USA). The accelerometer 
is a small and light device that monitors wearers’ daily 
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PA and energy expenditure. Participating patients wear 
the accelerometer attached at their hip level for 1 week 
continuously during walking hours, in order to ensure 
the minimum of 4 full- day recordings as recommended 
by activity monitoring reviewers and experts.68 69 Different 
algorithms are chosen from the software provided by the 
manufacturer, ActiLife6 (ActiGraph, Pensacola, Florida, 
USA), to discriminate between low PAs and split patients 
in three activity intensity categories (sedentary, light and 
moderate)70 and to obtain patients’ energy expenditure 
in kilocalories71 and MET.72 The daily and weekly time in 
hours and percentage of time spent in each of the activity 
intensity categories as well as the estimated energy expen-
diture in both kilocalories and MET are collected.
Reported functioning
Data from this domain are obtained from four question-
naires sent to patients and filled up by them via internet. 
All the questionnaires require 10–15 minutes to be filled 
in.
 ► Physical functioning (Rand36 Physical Functioning 
subscale—Rand36- PF). The Rand36 is a health- related 
quality of life survey that measures the impact of 
health on patients’ well- being and ability to function. 
Patients are asked to answer only the Physical Func-
tioning (PF) subscale which looks at the limitations 
patients experience during their daily activities. Each 
of the 10 items belonging to the PF subscale has a 
three- level response choice ranging from 0 (limited a 
lot) to 100 (not limited at all), the total average score 
ranges from 0 to 100 too; where a higher score is asso-
ciated with a greater limitation in performing daily 
activities. For the purposes of the study, the Dutch 
translation of the Rand36 is used, which has shown 
good internal consistency (Cronbach’s α=0.92) and 
test–retest reliability (r=0.72–0.82) in the general 
population.73 74
 ► Disability (Pain Disability Index—PDI). The index is a 
7- item questionnaire which measures the interference 
of pain with the ability to function in different daily 
life activities: family/home responsibilities, recrea-
tion, social activity, occupation, sexual behaviour, self- 
care and life support activity. Each item ranges from 0 
(no interference) to 10 (total interference), and the 
total score ranges from 0 to 70; where scoring higher 
is associated with higher interference in daily life 
activities. The PDI has shown modest test–retest reli-
ability (r=0.44) and high internal consistency (Cron-
bach’s α=0.86) in patients with chronic pain.75 For 
the purposes of the study the Dutch translation of the 
PDI is used, which has shown a good internal consist-
ency (Cronbach’s α=0.85) and test–retest reliability 
(ICC=0.76) in patients with musculoskeletal pain.76
 ► Work ability (Work Ability Score—WAS). The score is 
a single- item question which compares patient’s 
current work ability with their lifetime best. The result 
is a score ranging from 0 (unable to work) to 10 (best 
working ability). The single- item question is part of 
the Work Ability Index (WAI), a questionnaire which 
measures work ability and has shown to be test–retest 
reliable (difference between test and retest=−0.53) 
in construction workers.77 The WAS has shown to be 
highly correlated to the 28 items of the WAI among 
women on a long- term sick leave (r=0.87)78 and 
among active workers (r=0.63).79
Supplementary measurements
Demographic characteristics
Patients fill in a form with their details when the QST 
assessment takes place. Such details include: age, sex, 
nationality, height, weight, pain characteristics (affected 
body area, duration and medication, if applicable), 
educational level and employment characteristics (work 
status and physical work demands per Dictionary of Occu-
pational Titles).80
Pain-related questionnaires
 ► Pain intensity (Visual Analogue Scale—VAS Pain). The 
scale is a single- item question to assess the current pain 
intensity in adults. It is a straight line with ‘no pain’ 
(score=0) at one end and ‘pain as bad as it could be’ 
(score=100) at the other, in which patients are asked 
to mark the line at the level that represents their pain 
level. The score is the distance between the mark and 
the ‘no pain’ end, where scoring higher is associated 
with greater pain intensity. The VAS Pain has shown 
good validity (r=0.62–0.91) and good test–retest relia-
bility (literate r=0.94 and illiterate r=0.71) in patients 
with rheumatic pain conditions.81 VAS Pain is sent to 
patients and filled in by them via internet along with 
the battery of functioning questionnaires (described 
above), that is, at baseline and weekly during the 
interdisciplinary rehabilitation programme.
 ► Body response to a straining exercise (Pain Response Ques-
tionnaire—PRQ).82 The questionnaire assesses the 
pain intensity of the different body locations on an 
11- point numeric scale (NRS) ranging from 0 (no 
pain) to 10 (worst pain imaginable), and the type of 
pain felt (muscle soreness, other, both or unknown). 
Additionally, it controls for the use of medication and 
for the performance of any other strenuous PA. For 
the purposes of this study, the body locations meas-
ured are predefined to four and the questionnaire is 
being filled in on three occasions: before the CPET, 
immediately afterwards and 24 hours later. PRQ 
is filled up at the same moment when the aerobic 
capacity test is performed (ie, during baseline and 
discharge assessments).
Psychological screening questionnaires
These questionnaires measure psychosocial features 
common to CSS that have demonstrated to affect pain 
experience and functioning.83 Patients fill in the ques-
tionnaires via internet that are sent per CAU procedures 
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 ► Pain Catastrophizing Scale (PCS). The 13- item question-
naire measures in a 5- point Likert scale (0—not at 
all, 4—all the time) the degree to which patients have 
had catastrophic thoughts or feelings during their 
pain experience and accounts for three subscales or 
dimensions: rumination, magnification and helpless-
ness.84 For the purposes of the study the Dutch trans-
lation of the PCS is used,85 which has shown good 
internal consistency (Cronbach’s α=0.85–0.91) and 
test–retest reliability (r=0.92) among healthy individ-
uals (students) and patients with CLBP.86
 ► Injustice Experience Questionnaire (IEQ). The 12- item 
reported questionnaire assesses in a 5- point Likert 
scale from (0—never, 4—all the time) four different 
aspects of the perceived injustice due to injury: 
severity, blame, unfairness and irreparability. The 
questionnaire has shown to have good internal consist-
ency (Cronbach’s α=0.92) and test–retest reliability 
(ICC=0.98) in a group of patients with fibromyalgia.87 
For the purposes of the study the Dutch translation of 
the IEQ is used, as translated by the Pain in Motion 
group.88
 ► Brief Symptom Inventory (BSI). The inventory is a 53- item 
reported questionnaire which assesses patient’s 
current level of psychological distress with 5- point 
Likert scale questions (0—not at all, 4—extremely), 
the amount of symptoms present and their severity.89 
BSI is composed of nine subscales: somatisation, 
obsession- compulsion, interpersonal sensitivity, 
depression, anxiety, hostility, phobic anxiety, paranoid 
ideation and psychoticism. For the purposes of the 
study the Dutch translation of the BSI is used, which 
has shown good internal consistency (Cronbach’s 
α=0.71–0.87) and test–retest reliability (r=0.71–0.89) 
among psychiatric outpatient and healthy individual 
groups.90
Sample size
Due to the limited amount of relevant previous or similar 
studies, the sample sizes for the several analyses described 
in this research protocol are estimated a priori with 
GPower (G*Power for Windows, Version 3.1.9.2), and are 
exploratory as a result.
The following sample size calculations, as well as 
the planned statistical analyses later described, will be 
performed with proxies for the main variables. Addition-
ally, due to the influence of patient’s sex and age in the 
assessment outcomes, all analyses will include these vari-
ables for a moderator effect.
 ► Sample size for objective 1: to analyse the association between 
instruments assessing reference symptoms and signs attrib-
uted to CS. Correlation analyses will be performed for 
this objective. The correlation between the different 
CS measurements is expected to be weak as reported 
on associations between certain CS measures and 
tests.24 For a correlation coefficient of 0.25, an α error 
probability of 0.05 and a power of 0.8, a minimum 
sample size of 97 is calculated.
 ► Sample size for objective 2: to analyse whether reference 
symptoms and signs attributed to CS are associated with 
functioning measurement outcomes; and for objective 3: to 
analyse whether changes (between baseline and discharge) in 
reference symptoms and signs attributed to CS are related to 
changes in each of the functioning measurement outcomes. 
Multiple regression analyses will be performed 
for objectives 2 and 3. Based on the associations 
between CSI and psychosocial and cognitive behav-
ioural factors,24 25 the effect size is hypothesised to be 
medium. Since minimally three CS measurements 
are tested with sex and age required as independent 
variables, and controlled for the confounding effect 
of other demographic and test- related variables, 
eight predictors are foreseen. Taking into account 
the factors mentioned above, the sample size calcu-
lation results in a minimum of 77 patients, calculated 
with an α error probability of 0.05 and a power of 0.8. 
Finally, patients measured at discharge could be about 
30% less than at baseline due to either not following 
the interdisciplinary rehabilitation programme or 
personal reasons; a sample size of 110 patients may 
be required in this scenario.
Analyses
Data records from the different tests and questionnaires 
will be collected and merged into one database. The 
database management will be done by the project team 
and handled according to the internal regulations of the 
UMCG. The analyses of the study will be performed with 
SPSS software version 22.0 (IBM).
Before any analysis, data will be prepared:
 – Variables need to be calculated: body mass index; 
DMA, WUR and CPM tests (see the Methods and anal-
yses section, Measurements: CS measurements); PDI, 
Rand36- PF, PCS, BSI and IEQ questionnaires.
 – HRV: data will be preprocessed to correct for any arte-
facts that may be present at the beginning or at the end 
of the recording.
 – QST: the overall value of each sensory test is the mean 
at the most painful location and the five control loca-
tions together, provided that at most two locations are 
missing.
 – To perform the analyses to respond to objective 3, delta 
scores are computed (difference in scores between 
baseline and discharge) for CS, functioning and those 
confounder variables which are also measured at the 
same time points as the main measurements.
Proxies of the main measurements were selected to 
perform analyses. CS variables are: the sum score of CSI 
part A and the RMSSD for HRV. For QST, no variables 
are predefined, variables that correlate most strongly 
with each of the functioning measures will be selected. 
Functioning variables are: the maximal weight lifted for 
lifting capacity, the VO2max/kg for the maximal aerobic 
capacity, the daily vector magnitude (VM) counts for PA 
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The presence of missing data will be checked. If a vari-
able has more than 10% of missing data cases, its distri-
bution will be further examined. When the distribution 
of missing data is missing completely at random, anal-
yses with pairwise deletions are planned. If data are not 
missing completely at random, other suitable solutions 
will be applied such as multiple imputation.91 Regarding 
the presence of outliers, cases at 3 SD from the mean 
will be considered as outliers. Their influence will be 
measured using Cook’s distance and leverage values. 
When the outliers are not statistically influential and/or 
there is rationale for the outlier, no further actions are 
planned. The descriptive statistics of the sample charac-
teristics and main test results will be at this point calcu-
lated; numerical variables as mean and SD in normally 
distributed data and as median and IQR (25–75)) in non- 
normally distributed data, and categorical variables as 
counts and percentage of each category level.
 ► Statistical approach for objective 1: to analyse the associa-
tion between instruments assessing reference symptoms and 
signs attributed to CS. Multiple partial correlation anal-
yses will be performed and corrected for potential 
confounders. CS measurements will be the main vari-
ables and sex and age will be covariates. Additional 
covariates may enter the partial correlations based 
on their correlation coefficient with CS instruments 
and if p<0.01. Results will be reported as correlation 
coefficients (Pearson’s r and/or Spearman’s rho) and 
p values, with and without controlling for covariates. 
The significance level for all analyses is established at 
0.01, to account for the potential type I error due to 
the multitude of partial correlation analyses.
 ► Statistical approach for objective 2: to analyse whether refer-
ence symptoms and signs attributed to CS are associated with 
functioning measurement outcomes. First, multiple corre-
lation analyses, followed by multiple regression anal-
yses with data obtained at baseline, will be performed. 
Each of the main outcomes from functioning measure-
ments will be introduced in the models as dependent 
variable, CS measurements as independent variables, 
and sex, age and other demographic characteristics 
and/or test- related variables as potential confounders 
and/or moderators.
 ► Statistical approach for objective 3: to analyse whether changes 
(between baseline and discharge) in reference symptoms and 
signs attributed to CS are related to changes in each of the 
functioning measurement outcomes. A similar approach to 
objective 2 will be performed: first, multiple correla-
tion analyses will be performed with data obtained at 
baseline and discharge, followed by multiple correla-
tion analyses using delta scores of the data and, finally, 
multiple regression analyses again using delta scores. 
As in objective 2, each of the main outcomes from 
functioning measurements will be introduced in the 
models as dependent variable, CS measurements as 
independent variables, and sex, age and other demo-
graphic characteristics and/or test- related variables as 
potential confounders and/or moderators.
Confounders entering the final models of objectives 2 
and 3 will be selected based on their partial correlation 
coefficient with CS and functioning, and they will be 
included if p≤0.10. All multiple regression models will 
have the assumptions checked. Results of objectives 2 and 
3 will be reported as coefficient (b), CIs (95% CI), p values 
and explained variance, with and without controlling 
for confounders and/or moderators. Due to the large 
amount of correlation analyses and the risk of high type I 
error, a stricter significance level for correlation analyses 
is established, p<0.01. For multiple regression analyses 
the significance level is at 0.05.
dISCuSSIon
Several patients with CLBP have shown common mani-
festations with other chronic pain conditions, which may 
evidence the presence of CS in these patients. Yet, knowl-
edge on CS, especially in patients with CLBP, and on its 
association with functioning is developing. This research 
protocol aims to bridge that gap of knowledge with a 
novel approach. In the first place, the study (objective 
1) will describe the mechanisms of CS in patients with 
CLBP using instruments that assess reference symptoms 
of CS from different perspectives. Furthermore, the 
study (objectives 2 and 3) will also analyse longitudinally 
whether the presence of CS and changes of CS can be 
associated with changes in physical functioning perfor-
mance, for which functioning will be assessed with several 
objective monitoring and capacity tests, and self- reported 
measurements.
Within the constraints of CAU and in the absence 
of a single gold standard instrument that can diagnose 
CS, in this research protocol multiple instruments have 
been selected to examine reference symptoms and signs 
attributed to CS. (1) The hypersensitivity unrelated to 
mechanical stimulus is assessed with CSI. A questionnaire 
designed to measure CS, as it has been shown to be asso-
ciated to factors known to contribute to CS and is able 
to identify somatic and emotional symptoms related to 
CSS.24 38 92 (2) The disproportionate pain, diffuse distri-
bution, and allodynia and hyperalgesia are measured with 
QST. The QST is a battery of non- invasive standardised 
tests that assists in the identification of sensory and pain 
thresholds, the determination of pain intensity percep-
tion and the assessment of the CPM. Its results can allow 
pain characterisation (phenotyping) and processing, 
and monitoring its progression.93–97 (3) The low vagal 
nerve activity is examined with HRV. A non- invasive stan-
dardised measure that characterises the function of the 
ANS.34 The somatic and emotional symptoms related to 
CSS may generate an imbalance between a hyperactiva-
tion of the sympathetic tone and a reduction of the para-
sympathetic/vagal tone.34 98 99 (4) Psychosocial factors are 
measured with psychological screening questionnaires 
for perceived injustice (IEQ), catastrophising (PCS) and 
psychological distress (BSI). These psychosocial factors 
have shown a consistent effect on functioning and on 
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symptom beliefs and pain behaviours, which are common 
in patients with chronic pain, including CSS. Therefore, 
although not necessary for the clinical classification of 
CS, these factors are included in the study and potentially 
in the analyses. Some of the CS assessment instruments 
used in this study are more acknowledged than others in 
CS literature. CSI is widely used to measure CS since it 
was designed as a proxy for it; however, its internal consis-
tency and reliability in patients with CLBP has not yet 
been made available. Also, evidence is currently piling up 
on the necessity of routinely implementing the elements 
of QST relevant to patients’ conditions in clinical prac-
tice, given its ability to assess the somatosensory func-
tion,97 100 even though evidence in patients with CLBP is 
limited. Finally, literature on HRV as an instrument that 
may reflect an imbalance of ANS in patients with chronic 
pain conditions (specifically in those patients who have 
shown an overlap in the CS symptoms) is scarce.101 We are 
confident that the selected CS assessment instruments are 
considered the best available and combined will be able 
to comprehensively measure from the different refer-
ence clinical symptoms and signs indicative of CS being 
present. This will provide further insights on the mech-
anisms of CS and assist on the phenotyping of centrally 
sensitised patients with CLBP.
Various functioning assessments are selected for the 
research protocol to determine the functioning status of 
centrally sensitised patients with CLBP, including several 
objective monitoring and capacity tests, and self- reported 
measurements. (1) The floor- to- waist lifting capacity test is 
a physical assessment from the FCE that has demonstrated 
the best predictability for return to work in CLBP.102 (2) The 
aerobic capacity, expressed as VO2max, can be best assessed 
with a maximal aerobic capacity test such as the CPET. The 
cycle ergometer and the treadmill are the most used assess-
ments for aerobic capacity, but the cycle ergometer is most 
appropriate for patients.37 (3) The PA is measured by an 
accelerometer, an easy wearable activity- monitoring device 
that provides objective measurements of PA levels and PA 
distribution or patterns. (4) Patient- reported functioning 
questionnaires show patients’ pain experience, how they 
perceive or believe their functioning and participation is. 
The WAS, PDI and Rand36- PF show the advantage of being 
of short length and easy to interpret, due to their interval 
scale. Although questionnaire results can differ from 
their actual physical performance, both measurements 
complement each other. Furthermore, together they may 
provide a more comprehensive overview of patients with 
CLBP.103–105 Assessments such as lifting capacity and self- 
reported measurements have been routinely used to deter-
mine the functioning status of patients with CLBP. CPET, 
on the other hand, despite being scientifically superior to 
a submaximal aerobic capacity test, has barely been imple-
mented with patients with CLBP. As a result, it is unknown 
whether a maximal CPET could be applied systematically 
with these patients and their pain response to it. Moreover, 
even if there is a large amount of literature on PA, the meth-
odology implemented is very broad regarding population 
groups and/or measuring instruments, which hinders the 
synthesis of the understanding of PA of patients with CLBP. 
To bridge the gap, it may be of use an objective measurement 
of PA and monitored with accelerometers such as those of 
ActiGraph, which has shown to produce the most reliable 
devices for recording PA in free- living conditions.106 107 It 
is believed that the assessments described are suitable and 
relevant for the purpose of measuring functioning from 
multiple domains; and that the extended knowledge and 
the better understanding of the mechanisms involved 
obtained is not limited to CLBP but can be extended to CS.
Data collected for this project are large and the 
measurements of CS and functioning collected involve 
a broad amount of variables. As a result, proxies will be 
used for the statistical analyses. Previous research in CS 
assessments, on the one hand, and in functioning assess-
ments, on the other, have reported different methodolo-
gies and outcome parameters. The reason for which, even 
if authors have selected the proxy variables based on their 
relevance and/or contribution to the purposes of the 
current studies, the selection of the following measure-
ments as proxies may not be beyond debate: for HRV the 
RMSSD, as it is a measurement of the parasympathetic/
vagal tone which is not influenced by breathing108; for the 
maximal aerobic capacity the VO2max corrected for the 
body mass of the individual, due to the effect of body mass 
on VO2max; and for PA the daily VM counts, because it 
characterises movement duration and intensity.109
There are circumstances that might have influenced 
the results, in spite of the team’s efforts to obtain the 
most extensive insights of CS and its association with func-
tioning. To begin with, it should be considered that patients 
participating in the study are volunteers. Moreover, the 
exclusion criteria, despite being based on patients’ files, 
are also dependent on doctor’s judgement. The impact 
of these circumstances is so far unknown to the authors. 
Likewise, given the CAU design of the study the choice 
of measurements has to be feasible and compatible with 
the regular clinical procedures. As a consequence, the 
functional MRI, a commonly mentioned instrument to 
measure CS, could not be performed in the study. The 
HRV, on the other hand, although less often used, can be 
an insightful and innovative approach to the assessment 
of one of the indicators of CS. Additionally, the sample 
sizes are estimated a priori for the analyses due to insuffi-
cient previous studies and, therefore, they are of explor-
atory nature and used as a guide. Also, despite the efforts 
of the team to promote the study participation and partic-
ipant retention, it is likely that patient recruitment may be 
slower than anticipated and that the patient may not have 
a complete follow- up. However, since the measurement 
period is ample, the calculations are vigilantly made with 
generous margins (see the Methods and analyses section, 
Sample size), and the literature related to the topic has 
shown smaller sample sizes.25 28 110 We remain positive 
about the sample size and expect to have more than 
enough participants to perform analyses with sufficient 
power. Also, for comparability purposes, measurements 
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are planned to take place within 3 weeks from the Pain 
Rehabilitation team’s baseline and discharge assessments. 
The CSI, PDI and psychological screening questionnaires 
during baseline assessment are sent to be filled up 6 weeks 
before the rest of the measurements are obtained, a 
time distance due to waiting list time. Measurements are 
expected to be comparable to the rest of measurements 
at baseline, since no important changes are foreseen in 
patients regarding medication, surgery or personal condi-
tions during this time, and questionnaires have shown 
to have good clinimetric properties. As opposed to the 
limitations presented, given the large amount of correla-
tions in the multiple correlation analyses and the risk of 
type I error, a more strict significance level was applied, 
that is, 0.01. Also, for the QST the proxy will be selected 
per functioning outcome to obtain the most informative 
somatosensory measurement for each of the functioning 
measurements. We are confident that the results obtained 
will provide meaningful and valuable information.
All things considered, the results obtained from the 
measurements described in this research protocol can, 
first, help better describe and understand the mechanisms 
involved in CS, particularly the ones affecting the func-
tioning of patients with CLBP; and second, can be used 
to optimise the effectiveness of pain management inter-
ventions. To the authors’ knowledge, the study described 
in this research protocol is the first of its kind and it may 
become an important breakthrough for researchers 
involved in the study of pain, for the treatment strategy 
of patients with chronic pain by healthcare professionals 
and for patient’s pain education.
EThICS And dISSEMInATIon
All participating patients sign the informed consent 
before any assessment takes place. Formal ethical clear-
ance to perform the study has been obtained from the 
Medical Research Ethics Committee (METc) of the 
University Medical Center Groningen (the Netherlands) 
in July 2017 (METc 2016/702). All procedures are in 
accordance with the ethical standards of the Helsinki 
Declaration of 1975 as revised in 2014111 and with Dutch 
regulations of the Medical Research Involving Human 
Subjects Act, in Dutch: Wet Medisch- Wetenschappelijk 
Onderzoek, amended in 2018.112
The dissemination strategy of the research study results 
will be through scientific publications in peer- reviewed 
journals and presentations in relevant national and inter-
national conferences. In addition to it, reports will be sent 
by post to participants, and reports and presentations in 
meetings will be provided to stakeholders.
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